MTOR and cholangiocarcinoma: To provide further conclusive evidence in vivo experiments, we will further demonstrate the therapeutic effect of the PI3K/AKT/mTOR signaling pathway inhibitors on CCA with high DCLK1 expression by constructing animal models.